Take chicks as an example: Rummeliibacillus stabekisii CY2 enhances immunity and regulates intestinal microbiota by degrading LPS to promote organism growth and development

Abstract

Human and animal organisms are in a state of low-grade inflammation caused by low concentrations of LPS. The novel potential probiotic Rummeliibacillus stabekisii CY2 was pre-proven in vitro to reduce LPS. Explored its effect in vivo, chicks were fed in different groups (0, CY2L, and CY2H). Results showed that CY2H had significantly lower serum levels of LPS and the inflammatory factors IL-1 and IL-6, reduced low-grade inflammatory levels, and significantly higher levels of the inflammatory inhibitory factor IL-10. The structure of the chicks’ intestinal microbiota was improved. The relative abundance of the potentially probiotic Lactobacillales increased significantly. Importantly, the growth performance of chicks has been significantly improved. In conclusion, CY2 supplementation can improve immunity through the degradation of LPS, alleviate low-grade inflammation, improve intestinal microbiota, and thus promote the growth of the chicks.

Keywords

• Rummeliibacillus stabekisii
• Immunity
• Lipopolysaccharide
• Intestinal microbiota
• Growth performance